Public Policy Resources

Share

The Landscape of Biomarker Testing Coverage in the U.S.

February 28, 2022

Biomarker testing is becoming increasingly important for cancer care because it connects the right patient, to the right treatment, at the right time, however insurance coverage of testing varies widely. This study, that examines administrative claims data to understand the premium impact of expanding biomarker testing coverage in four markets: commercial self-insured large group, small group, individual, and Medicaid, found a small potential impact on insurance premiums as a result of higher utilization of biomarker testing.

PDF icon Download Landscape of Biomarker Testing Coverage in the U.S.

Related Resources

Equidad en salud en las pruebas de biomarcadores y terapias dirigidas

February 15, 2024

La terapia dirigida puede mejorar la supervivencia y la calidad de vida al conectar a los pacientes con el tratamiento más beneficioso para su enfermedad.

Read more

Survivor Views: One in Ten Impacted by Recent Drug Shortages

October 19, 2023

The nation’s drug shortage crisis continues to affect cancer patients and survivors with 1 in every 10 (10%) reporting impacts to care, a majority of whom have had difficulties finding substitute medications (68%) and cited treatment delays (45%).

Read more